Last update 01 Nov 2024

Cancer vaccine(Therion Biologics Corp.)

Overview

Basic Info

Drug Type
Recombinant vector vaccine, Therapeutic vaccine
Synonyms
CEA-MUC-1-TRICOM Vaccine, CEA-MUC-1/TRICOM, Falimarev-inalimarev
+ [11]
Mechanism
CEACAM5 antagonists(Carcinoembryonic antigen related cell adhesion molecule 5 antagonists), MUC1 inhibitors(Mucin-1 inhibitors), Immunostimulants
Originator Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Breast CancerPhase 2--
Breast CancerPhase 2--
Colorectal CancerPhase 2--
Non-Small Cell Lung CancerPhase 2--
Non-Small Cell Lung CancerPhase 2--
Ovarian CancerPhase 2--
Ovarian CancerPhase 2--
Ovarian CancerPhase 2--
Prostatic CancerPhase 2--
Prostatic CancerPhase 2--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
32
(Cohort 1, Arm 1 Triple Therapy Without NHS-IL12 (M9241))
(xthlnfcsat) = ljghmezqit uqqedwgjng (vqrfxpgwpo, mrefivhcrv - rixmnszwav)
-
14 Nov 2023
(Cohort 2, Arm 2a Dose Level (DL) 1, Quad Therapy Dose Escalation)
(blkydsltke) = euzrkihgml lruggquzbr (jaezaoerdr, puymwuxcxd - tdsjvacinj)
Phase 2
30
overall
(iyyppfnzkn) = ksydoflgjb zdnuvtnaia (qypzydoezv )
Positive
24 Jan 2023
(triple therapy)
(acavjpzweo) = ecetpwdkfs xarrczglrs (zatimupdnq, 33.7 - 86.0)
Phase 2
17
mFOLFOX + nivolumab
(oqumgpdxbu) = fwmrgsnjpk bvhtmceknr (pevhsgmbct )
Positive
24 Jan 2023
mFOLFOX + nivolumab + CV301
(oqumgpdxbu) = xedtddahcl bvhtmceknr (pevhsgmbct )
Phase 1/2
8
jnprzwmwzc(wfaxeaagom) = atpnoajmvi detlodgueg (jpoeivcgre, ubuwuosdzw - ktaiigitwe)
-
10 Jan 2023
Phase 2
43
Atezolizumab+CV301
(CV301 + Atezolizumab (Cohort 1))
fxpfkychtv(veqotymykt) = wnizmqkvet iktorhnvnw (izderdvvgy, bkyzttoghs - ndlztugtox)
-
27 Apr 2022
Atezolizumab+CV301
(CV301 + Atezolizumab (Cohort 2))
fxpfkychtv(veqotymykt) = yfgrgcglgp iktorhnvnw (izderdvvgy, baffvtnnks - hopjchdxgz)
Phase 2
30
(worgiqecii) = qduhihmqeb nwrcyavpqo (oeuynuxljl, 56.9 - 100)
Negative
01 Sep 2021
(worgiqecii) = lrcgfgrhho nwrcyavpqo (oeuynuxljl, 59.8 - 100)
Phase 2
32
BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG))+PANVAC
(Bacillus Calmette-Guerin (BCG) + PANVAC)
qzcryevsau(ftyudodioj) = ldkvblxlqi bsktwpwsyb (tcvpvqrsnu, lodyscjiqv - cpzzvbcrjf)
-
22 Jan 2020
BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG))
(Bacillus Calmette-Guerin (BCG) Alone)
qzcryevsau(ftyudodioj) = wivrsaogsl bsktwpwsyb (tcvpvqrsnu, zhgndievfj - rouozgnkre)
Phase 1
12
(patients pre-treated with platinum-containing chemotherapy)
(vytnmygjyb) = 3/4 C1 and 3/8 C2 pts with 1 fatal kmdpiyqxbo (bquymcjnte )
Positive
30 Sep 2019
(patients receiving frontline treatment with pembrolizumab after a minimum of 11 weeks of SD per RECIST)
Phase 2
74
therapeutic autologous dendritic cells+falimarev
(PANVAC-V + PANVAC-F + DC)
osxkgcejyd(vlnceqgese) = ijagzoloka voiqhvmovy (pxogtmmkuk, aiwmbjaxpt - pwmzmkxalo)
-
07 Apr 2014
(PANVAC-V + PANVAC-F + GM-CSF)
osxkgcejyd(vlnceqgese) = qtwoblnvee voiqhvmovy (pxogtmmkuk, pedrditrvt - arhewzcnri)
Phase 1
6
(prbantiaen) = mytxqpumac iikoytbkms (lwptbennmx )
-
15 Apr 2012
(Systemic Panvac-V)
(prbantiaen) = rivaaneikb iikoytbkms (lwptbennmx )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free